Non-invasive detection of protein aggregation in biopharmaceuticals using TD-NMR and MRI

IF 4.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Gozde Ozesme Taylan , Hani Alam , Erdem Mercan , Ece Erkan , Cem Yamali , Mecit Halil Oztop
{"title":"Non-invasive detection of protein aggregation in biopharmaceuticals using TD-NMR and MRI","authors":"Gozde Ozesme Taylan ,&nbsp;Hani Alam ,&nbsp;Erdem Mercan ,&nbsp;Ece Erkan ,&nbsp;Cem Yamali ,&nbsp;Mecit Halil Oztop","doi":"10.1016/j.ejpb.2025.114830","DOIUrl":null,"url":null,"abstract":"<div><div>With the rapid expansion of biotechnological drugs, ensuring their quality has become essential. Proper storage and transportation are critical to maintaining drug stability and efficacy. This study investigates protein aggregation, a major quality concern in biopharmaceuticals, using low-field NMR, Time Domain NMR and Magnetic Resonance Imaging (MRI), as a non-invasive, rapid alternative to conventional analytical methods. For the first time, MRI, T<sub>2</sub> relaxation times, and T<sub>2</sub> relaxation spectra were applied to detect aggregation in Humulin R, a low-concentration subcutaneous insulin. Aggregation was induced by heat and agitation to simulate improper handling. MRI effectively distinguished control and stressed samples, while T<sub>2</sub> relaxation measurements differentiated stress conditions. Additionally, T<sub>2</sub>-Inverse Laplace Transform (<em>ILT</em>) indicated aggregate size, aligning with particle size analysis and validating the novel approach. These findings highlight the potential of low-field NMR for biopharmaceutical quality assessment.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"215 ","pages":"Article 114830"},"PeriodicalIF":4.3000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939641125002073","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

With the rapid expansion of biotechnological drugs, ensuring their quality has become essential. Proper storage and transportation are critical to maintaining drug stability and efficacy. This study investigates protein aggregation, a major quality concern in biopharmaceuticals, using low-field NMR, Time Domain NMR and Magnetic Resonance Imaging (MRI), as a non-invasive, rapid alternative to conventional analytical methods. For the first time, MRI, T2 relaxation times, and T2 relaxation spectra were applied to detect aggregation in Humulin R, a low-concentration subcutaneous insulin. Aggregation was induced by heat and agitation to simulate improper handling. MRI effectively distinguished control and stressed samples, while T2 relaxation measurements differentiated stress conditions. Additionally, T2-Inverse Laplace Transform (ILT) indicated aggregate size, aligning with particle size analysis and validating the novel approach. These findings highlight the potential of low-field NMR for biopharmaceutical quality assessment.

Abstract Image

利用TD-NMR和MRI无创检测生物制药中蛋白质聚集
随着生物技术药物的迅速发展,确保其质量变得至关重要。适当的储存和运输对保持药物的稳定性和有效性至关重要。本研究利用低场核磁共振、时域核磁共振和磁共振成像(MRI)作为传统分析方法的非侵入性、快速替代方法,研究了生物制药中一个主要的质量问题——蛋白质聚集。首次应用MRI、T2弛豫时间和T2弛豫谱检测低浓度皮下胰岛素Humulin R的聚集。通过加热和搅拌引起聚集,模拟不适当的处理。MRI可有效区分对照和应力样品,而T2松弛测量可区分应力条件。此外,t2 -拉普拉斯逆变换(ILT)显示了骨料粒度,与粒度分析一致,验证了新方法。这些发现突出了低场核磁共振在生物制药质量评估中的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.80
自引率
4.10%
发文量
211
审稿时长
36 days
期刊介绍: The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics. Topics covered include for example: Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids) Aspects of manufacturing process design Biomedical aspects of drug product design Strategies and formulations for controlled drug transport across biological barriers Physicochemical aspects of drug product development Novel excipients for drug product design Drug delivery and controlled release systems for systemic and local applications Nanomaterials for therapeutic and diagnostic purposes Advanced therapy medicinal products Medical devices supporting a distinct pharmacological effect.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信